Survival benefit for patients treated in a certified head and neck tumor center.
Journal
European review for medical and pharmacological sciences
ISSN: 2284-0729
Titre abrégé: Eur Rev Med Pharmacol Sci
Pays: Italy
ID NLM: 9717360
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
entrez:
20
4
2019
pubmed:
20
4
2019
medline:
9
9
2020
Statut:
ppublish
Résumé
Increasing effort has been put in the implementation and certification of head and neck tumor centers in order to establish standardized, quality assured health care for head and neck tumor patients. This study evaluated survival rates after treatment in a certified head and neck tumor center (CHNTC) vs. a non-certified head and neck tumor center (non-CHNTC) in Middle Franconia, Germany. Age, sex, possible obituary, and typical relevant prognostic variables were analyzed. Diagnosis was recorded according to ICD10. Clinical and pathological TNM staging, tumor grading, localization, R-stage, and morphology were assessed (ICD-0). Patients diagnosed with oral cancer (N=1047) were divided into groups based on where they received their primary treatment; CHNTCs or non-CHNTCs. Patients treated at CHNTCs had significantly higher survival rates vs. those treated at non-CHNTC (p=0.023) in univariate analysis. In a Cox regression model, survival rates for patients with pN0 and pN+ stage were similar at both types of centers. Men with pN0 had significantly lower survival rates (HR=0.497, p<0.001). Age had a statistically significant influence on survival rates independently from pN stage (HR=1.031 per year, p<0.001 in both groups). Patients treated at CHNTC had better survival rates than those treated at non-CHNTC.
Identifiants
pubmed: 31002137
doi: 10.26355/eurrev_201904_17564
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM